#VisualAbstract: Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma
Click to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
Click to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
1. Median overall survival was greater in the pembrolizumab group compared to the control group (12.7 months vs. 10.9 months). ...
1. Median disease-free survival is longer in patients receiving mFOLFIRINOX as compared to those receiving gemcitabine. 2. Median overall survival ...
Click to read this study in the Journal of Clinical Oncology.
1. Median disease-free survival is longer in patients receiving mFOLFIRINOX as compared to those receiving gemcitabine. 2. Median overall survival ...
1. The use of a neoadjuvant gemcitabine-based chemoradiotherapy before surgery and adjuvant gemcitabine increased the overall survival rate when compared ...
Click to read this study in the Journal of Clinical Oncology.
Click to read the study in The Lancet Oncology.
1. Adavosertib plus gemcitabine showed improved progression-free and overall survival in platinum-resistant or refractory recurrent ovarian cancer versus gemcitabine plus ...
1. Adavosertib plus gemcitabine showed improved progression-free and overall survival in platinum-resistant or refractory recurrent ovarian cancer versus gemcitabine plus ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.